Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
neoDIRHP: De-escalation Neoadjuvant Therapy in HER2-positive Early Breast Cancer
NCT07748260Phase 3Not yet recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Sep 2026
- Primary completion
- Jul 2031
01
Overview
A Phase 3 trial of trastuzumab, pertuzumab in breast cancer, sponsored by Guangdong Provincial People's Hospital. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
trastuzumabpertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07748260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07748260.